Every week Bexis circulates an electronic mail with new, bloggable circumstances, however typically there are extra new selections than running a blog days, and circumstances get handed over.
Here are three (comparatively) latest examples
Gonzalez v. International Medical Devices, Inc., ___ F. Supp.3d ___, 2025 WL 2054361 (W.D. Tex. June 20, 2025), arose from the plaintiff’s obvious off-label use of a penile implant for “beauty enhancement” slightly than its meant therapeutic objective. Id. at *6. Needless to say, since Gonzalez is a product legal responsibility motion, there have been issues. The first important difficulty in Gonzalez was private jurisdiction over the out-of-state alleged inventor of the machine and his company. Plaintiff succeeded on particular private jurisdiction primarily based on allegations that, past sustaining an internet site, which wasn’t sufficient, id. at *5, he “purposefully” focused the jurisdiction (Texas) by offering device-related coaching to in-state surgeons and “licensing” them to make use of his invention. Id. at *5-6. That’s a degree that’s vital for inventors and smaller corporations to comprehend. Licensing and coaching physicians in use of a product has the potential to assist particular private jurisdiction within the discussion board the place the physicians who have been so instructed apply.
A Texas shopper fraud declare additionally survived (in the meanwhile) in Gonzalez. The allegation was that the defendants’ web site affirmatively misrepresented that the machine was “FDA-cleared” for a selected meant use when the precise clearance was for one thing else. Id. at *6. Potential allegations that defendants have some kind of heightened obligation to reveal FDA meant makes use of in off-label use circumstances at all times catches our eye as a result of we reject that FDA regulatory standing – versus medical dangers and advantages – are related to something plaintiffs should be informed in such litigation. However, Gonzalez seems to be totally different, alleging an precise misrepresentation, versus some unmet obligation to reveal. Id. Moreover, the Gonzalez allegations are most likely factually incorrect and thus unlikely to outlive as soon as the pleadings are pierced. Id. (refusing, on the pleadings, to entertain an argument that the plaintiff’s allegation was merely “flawed” as to “which iteration” of the machine had been implanted).
Finally, Gonzalez held that causation underneath the Texas discovered middleman rule was adequately pleaded, given allegations that the implanter “opined the older mannequin of the . . . Device was faulty and that he not offers [that kind of] implant surgical procedure attributable to his sufferers’ dissatisfaction.” Id. at *8. Ouch. Again, these are pleadings, the veracity of which is questionable, however to us they exhibit what TwIqbal actually requires for discovered middleman causation. We don’t see this kind of particular and detailed allegation usually, if in any respect, from plaintiffs.
Case #2 is Morrison v. Family Dollar Stores, LLC, 2025 WL 1368839 (Mag. S.D. Fla. May 5, 2025), which dismissed one other of those all-too-common OTC drug financial loss class actions. Plaintiffs alleged they “bought quite a few totally different over-the-counter (“OTC”) medicine and medical gadgets” from the defendant’s “shops in twenty states” and talked about a number of remembers for improper storage of their grievance. Id. at *1. They alleged “adulteration,” trying to benefit from precedent that gave such claims a free move on alleging injury-in-fact. Id. at *4-5.
Not sufficient – not practically. Their different allegations made clear that “adulteration” couldn’t be determined throughout the board:
[T]his case will not be about whether or not a product comprises an ingredient that renders it (each single unit of it) adulterated on the outset. Rather, Plaintiffs allege that the merchandise they bought grew to become adulterated as a result of they have been saved exterior of labeled temperature necessities. And whereas it’s believable, primarily based on Plaintiffs’ allegations, that some [of these] merchandise have been saved exterior of labeled temperature necessities, Plaintiffs’ allegations that they themselves bought such merchandise are speculative, not believable.
Morrison, 2025 WL 1368839, at *6 (footnote omitted). Plaintiffs alleged no info that merchandise they bought had the claimed storage issues. Their broad-brush allegations that all the things was “adulterated” have been “a conclusory label that’s not entitled to the belief of fact.” Id. (citations omitted). The grievance “beg[ged] the query of how one may conclude that the merchandise Plaintiffs bought have been ‘Adulterated Products.’” Id.
Transportation and storage-related circumstances are inherently individualized (which must also finally kill class certification, if Morrison ever acquired that far). The varied remembers couldn’t present the important inference. Id. at *7. For this proposition, Morrison cited what we referred to as the “silver lining” within the in any other case adversarial Huertas v. Bayer US LLC, 120 F.4th 1169 (3d Cir. 2024), choice: “The mere reality {that a} product was recalled wouldn’t nudge Plaintiffs’ claims throughout the road from conceivable to believable.” Morrison, 2025 WL 1368839, at *7 (quoting Huertas, 120 F.4th at 1178). Nor are remembers any kind of “admission” that each unit of each recalled product essentially had the recalled attribute. Id. (that was “not an inexpensive inference”).
Further, plaintiffs didn’t allege any info to determine that they really purchased recalled merchandise:
Plaintiffs merely allege that they bought these merchandise throughout the Class Period, with out alleging info exhibiting that they bought the merchandise throughout the related recall interval, a lot much less from the affected shops or within the affected states. But the Class Period exceeds 28 months. And for greater than 19 of these 28 months, no remembers have been in impact.
Id. The grievance established solely the “chance” that plaintiffs may have purchased recalled merchandise, not that they really did. Id. Nor may potential testimony from a “handful of former workers” suffice to create some overarching presumption that each product in all places was “adulterated.” Id. at *9. Again, the Huertas silver lining got here to the defendant’s rescue, because the remembers “had no relevance to the plaintiffs who didn’t allege they bought spray merchandise with the lot numbers within the recall,” and these plaintiffs pleaded no info supporting any buy of recalled merchandise. Id. at *11. In sum:
Plaintiffs have didn’t plausibly allege that any of the medicine or gadgets they bought from [defendant] have been adulterated. Nor have they plausibly alleged such widespread adulteration to the diploma that each single OTC drug and machine offered . . . at any retailer within the United States throughout the 28-plus month Class Period (together with Plaintiffs’ merchandise) was adulterated.
Id. Case dismissed for lack of standing. Even with an “adulteration” free move on injury-in-fact, the Morrison plaintiffs couldn’t get to first base underneath TwIqbal.
The third and closing case, In re Johnson & Johnson Talcum Powder Products Marketing, Sales Practices & Products Liability Litigation, 2025 WL 1334619 (D.N.J. May 7, 2025), concerned talc (clearly), slightly than prescription medical merchandise. The proposition it established, nevertheless – that mere unenacted FDA “proposals” aren’t admissible in product legal responsibility litigation – is extra more likely to recur in our sandbox than wherever else.
This ruling is brief and candy. In Talcum, plaintiffs sought both to “complement the report” or have “judicial discover” taken of a pending – not closing − FDA proposed rule regarding testing of talc-containing merchandise typically. Id. at *1. Both requests have been denied as a result of “the FDA has not accomplished its formal rulemaking course of.” Id. Plainly the proposal was “not closing,” so it couldn’t presumably “symbolize closing company motion.” Id. “Because present rules govern till the Proposed Rule turns into closing, the Court ‘decline[s] to take cognizance of the proposed regulation.’” Id. (quoting Depenbrock v. Cigna Corp., 389 F.3d 78, 85 (3d Cir. 2004)). The FDA proposal was not but in impact (in distinction to non-binding, however present, FDA steering) and thus couldn’t have any retroactive relevance to the litigation.
Given the present administration of the FDA, we don’t know what uncommon (or worse) proposals could also be coming down the pike. This Talcum order might be straight on level, ought to plaintiffs attempt to affect judges or juries with some off-the-wall future FDA proposal.